CN1957928A - Controlled release preparation of clinical treating medication, and fabricating method - Google Patents
Controlled release preparation of clinical treating medication, and fabricating method Download PDFInfo
- Publication number
- CN1957928A CN1957928A CN 200510104989 CN200510104989A CN1957928A CN 1957928 A CN1957928 A CN 1957928A CN 200510104989 CN200510104989 CN 200510104989 CN 200510104989 A CN200510104989 A CN 200510104989A CN 1957928 A CN1957928 A CN 1957928A
- Authority
- CN
- China
- Prior art keywords
- grams
- preparation
- sustained
- matrix material
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 259
- 229940079593 drug Drugs 0.000 title claims abstract description 176
- 238000000034 method Methods 0.000 title abstract description 106
- 239000003405 delayed action preparation Substances 0.000 title description 7
- 238000002360 preparation method Methods 0.000 claims description 136
- 229920002125 Sokalan® Polymers 0.000 claims description 98
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 97
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 97
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 97
- 239000000203 mixture Substances 0.000 claims description 96
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 92
- 229960001631 carbomer Drugs 0.000 claims description 92
- 238000007908 dry granulation Methods 0.000 claims description 79
- 238000013268 sustained release Methods 0.000 claims description 66
- 239000012730 sustained-release form Substances 0.000 claims description 65
- 239000011159 matrix material Substances 0.000 claims description 57
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 38
- -1 hydroxypropyl Chemical group 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 37
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 25
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 23
- 239000006187 pill Substances 0.000 claims description 23
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 23
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 23
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- 235000021355 Stearic acid Nutrition 0.000 claims description 22
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 22
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- 239000008117 stearic acid Substances 0.000 claims description 22
- 229960003022 amoxicillin Drugs 0.000 claims description 20
- 239000000654 additive Substances 0.000 claims description 19
- 239000000314 lubricant Substances 0.000 claims description 19
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 18
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 16
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000758 substrate Substances 0.000 claims description 16
- 239000001856 Ethyl cellulose Substances 0.000 claims description 15
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 15
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 15
- 229920001249 ethyl cellulose Polymers 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 229920002494 Zein Polymers 0.000 claims description 13
- 239000005019 zein Substances 0.000 claims description 13
- 229940093612 zein Drugs 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 10
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 8
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960003105 metformin Drugs 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 238000003801 milling Methods 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 5
- 229960004957 aprindine Drugs 0.000 claims description 5
- 229960000333 benzydamine Drugs 0.000 claims description 5
- 229960003719 cefdinir Drugs 0.000 claims description 5
- 229960002580 cefprozil Drugs 0.000 claims description 5
- 229950002506 cefteram pivoxil Drugs 0.000 claims description 5
- 229960002620 cefuroxime axetil Drugs 0.000 claims description 5
- 229960000590 celecoxib Drugs 0.000 claims description 5
- 229950011171 cinmetacin Drugs 0.000 claims description 5
- 229950011462 clorprenaline Drugs 0.000 claims description 5
- 238000007907 direct compression Methods 0.000 claims description 5
- 229960003276 erythromycin Drugs 0.000 claims description 5
- 229960004273 floxacillin Drugs 0.000 claims description 5
- 229960004580 glibenclamide Drugs 0.000 claims description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 229960000708 hexoprenaline Drugs 0.000 claims description 5
- 229960002474 hydralazine Drugs 0.000 claims description 5
- 229960003803 meclofenamic acid Drugs 0.000 claims description 5
- 229960003464 mefenamic acid Drugs 0.000 claims description 5
- 229960002545 methylthiouracil Drugs 0.000 claims description 5
- 229960002757 midecamycin Drugs 0.000 claims description 5
- 229960002497 nicorandil Drugs 0.000 claims description 5
- 229960001180 norfloxacin Drugs 0.000 claims description 5
- 229960004535 oxazepam Drugs 0.000 claims description 5
- 229960004570 oxprenolol Drugs 0.000 claims description 5
- 229960000989 perhexiline Drugs 0.000 claims description 5
- 229960002572 phenprobamate Drugs 0.000 claims description 5
- 229960002790 phenytoin sodium Drugs 0.000 claims description 5
- 229960002508 pindolol Drugs 0.000 claims description 5
- 229960004986 pyritinol Drugs 0.000 claims description 5
- 229960003147 reserpine Drugs 0.000 claims description 5
- 229960002052 salbutamol Drugs 0.000 claims description 5
- 229950006796 spiramycin ii Drugs 0.000 claims description 5
- 229960000195 terbutaline Drugs 0.000 claims description 5
- 229960002872 tocainide Drugs 0.000 claims description 5
- 229960005371 tolbutamide Drugs 0.000 claims description 5
- 229960001017 tolmetin Drugs 0.000 claims description 5
- 229960005334 tolperisone Drugs 0.000 claims description 5
- 229960004394 topiramate Drugs 0.000 claims description 5
- 229960005342 tranilast Drugs 0.000 claims description 5
- 229960003232 troxerutin Drugs 0.000 claims description 5
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 4
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 claims description 4
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 claims description 4
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims description 4
- SSMSBSWKLKKXGG-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-isopropylaminoethanol Chemical compound CC(C)NCC(O)C1=CC=CC=C1Cl SSMSBSWKLKKXGG-UHFFFAOYSA-N 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 4
- FSKFPVLPFLJRQB-UHFFFAOYSA-N 2-methyl-1-(4-methylphenyl)-3-(1-piperidinyl)-1-propanone Chemical compound C=1C=C(C)C=CC=1C(=O)C(C)CN1CCCCC1 FSKFPVLPFLJRQB-UHFFFAOYSA-N 0.000 claims description 4
- UIYAXIPXULMHAI-JLGRZTKVSA-N Cefteram pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 UIYAXIPXULMHAI-JLGRZTKVSA-N 0.000 claims description 4
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims description 4
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims description 4
- 239000001828 Gelatine Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 4
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 claims description 4
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 claims description 4
- CAMYKONBWHRPDD-UHFFFAOYSA-N Phenprobamate Chemical compound NC(=O)OCCCC1=CC=CC=C1 CAMYKONBWHRPDD-UHFFFAOYSA-N 0.000 claims description 4
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 4
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 claims description 4
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000836 amitriptyline Drugs 0.000 claims description 4
- 229940042746 amlodipine / benazepril Drugs 0.000 claims description 4
- NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 claims description 4
- 229950000900 bendazol Drugs 0.000 claims description 4
- 229940093265 berberine Drugs 0.000 claims description 4
- 229960000830 captopril Drugs 0.000 claims description 4
- 229960005003 carbocromen Drugs 0.000 claims description 4
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 4
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004588 cilostazol Drugs 0.000 claims description 4
- NKPPORKKCMYYTO-DHZHZOJOSA-N cinmetacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)\C=C\C1=CC=CC=C1 NKPPORKKCMYYTO-DHZHZOJOSA-N 0.000 claims description 4
- 229960001117 clenbuterol Drugs 0.000 claims description 4
- 229960001214 clofibrate Drugs 0.000 claims description 4
- 229960001585 dicloxacillin Drugs 0.000 claims description 4
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 4
- 229960005426 doxepin Drugs 0.000 claims description 4
- 229960003859 efloxate Drugs 0.000 claims description 4
- 229960003980 galantamine Drugs 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 4
- 150000002338 glycosides Chemical class 0.000 claims description 4
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 4
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 4
- 229960003404 mexiletine Drugs 0.000 claims description 4
- 229960002608 moracizine Drugs 0.000 claims description 4
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000564 nitrofurantoin Drugs 0.000 claims description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 4
- 229940100243 oleanolic acid Drugs 0.000 claims description 4
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 claims description 4
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 claims description 4
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002288 procaterol Drugs 0.000 claims description 4
- 229960000203 propafenone Drugs 0.000 claims description 4
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 4
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 4
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 claims description 4
- 229960000620 ranitidine Drugs 0.000 claims description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims description 4
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 claims description 4
- 229960004586 rosiglitazone Drugs 0.000 claims description 4
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 4
- 229920002545 silicone oil Polymers 0.000 claims description 4
- 229960004245 silymarin Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 4
- 235000011152 sodium sulphate Nutrition 0.000 claims description 4
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims description 4
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 4
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 claims description 4
- 229960000859 tulobuterol Drugs 0.000 claims description 4
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims description 3
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims description 3
- SRTZYSFUFGOMFR-FKLPMGAJSA-N 2-[(3s)-3-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 SRTZYSFUFGOMFR-FKLPMGAJSA-N 0.000 claims description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 3
- ZVXBAHLOGZCFTP-UHFFFAOYSA-N Efloxate Chemical compound C=1C(OCC(=O)OCC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZVXBAHLOGZCFTP-UHFFFAOYSA-N 0.000 claims description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 3
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 3
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 claims description 3
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 3
- 241000545405 Tripterygium Species 0.000 claims description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
- YTLQFZVCLXFFRK-UHFFFAOYSA-N bendazol Chemical compound N=1C2=CC=CC=C2NC=1CC1=CC=CC=C1 YTLQFZVCLXFFRK-UHFFFAOYSA-N 0.000 claims description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008139 complexing agent Substances 0.000 claims description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 3
- 229960005341 fenoprofen calcium Drugs 0.000 claims description 3
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- FUBVWMNBEHXPSU-UHFFFAOYSA-N moricizine Chemical compound C12=CC(NC(=O)OCC)=CC=C2SC2=CC=CC=C2N1C(=O)CCN1CCOCC1 FUBVWMNBEHXPSU-UHFFFAOYSA-N 0.000 claims description 3
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 claims description 3
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims description 3
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 claims description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004431 quetiapine Drugs 0.000 claims description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 3
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 3
- 235000017700 silymarin Nutrition 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 229960001344 methylphenidate Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- KSQIAZKOUOEHSA-UHFFFAOYSA-N Carbocromen hydrochloride Chemical compound [Cl-].CC1=C(CC[NH+](CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KSQIAZKOUOEHSA-UHFFFAOYSA-N 0.000 claims 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229930014456 matrine Natural products 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims 1
- 229960000488 tizanidine Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 239000007787 solid Substances 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 152
- 239000003826 tablet Substances 0.000 description 80
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 77
- 239000008101 lactose Substances 0.000 description 77
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 76
- 235000019359 magnesium stearate Nutrition 0.000 description 76
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 76
- 239000008108 microcrystalline cellulose Substances 0.000 description 76
- 229940016286 microcrystalline cellulose Drugs 0.000 description 76
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 74
- 239000000499 gel Substances 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 13
- 239000008187 granular material Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000007902 hard capsule Substances 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000013563 matrix tablet Substances 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- 229960002388 tizanidine hydrochloride Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZWUKMNZJRDGCTQ-UHFFFAOYSA-N Tizanidine hydrochloride Chemical compound Cl.ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 ZWUKMNZJRDGCTQ-UHFFFAOYSA-N 0.000 description 3
- 229960002793 amoxicillin sodium Drugs 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 description 2
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 2
- 229960001070 mexiletine hydrochloride Drugs 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960005197 quetiapine fumarate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- UABJPASVFPMIGE-KWZUVTIDSA-N (z)-but-2-enedioic acid;3-(diaminomethylidene)-1,1-dimethylguanidine;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.OC(=O)\C=C/C(O)=O.CN(C)C(=N)N=C(N)N.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O UABJPASVFPMIGE-KWZUVTIDSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CJTQARUHALKPGG-UHFFFAOYSA-N 2-benzyl-1h-benzimidazole;hydron;chloride Chemical compound Cl.N=1C2=CC=CC=C2NC=1CC1=CC=CC=C1 CJTQARUHALKPGG-UHFFFAOYSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- 235000001667 Vitex agnus castus Nutrition 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000009395 Zhengqing Fengtongning Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000011246 composite particle Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004060 dicloxacillin sodium Drugs 0.000 description 1
- SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960002861 doxepin hydrochloride Drugs 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940050868 moricizine hydrochloride Drugs 0.000 description 1
- GAQAKFHSULJNAK-UHFFFAOYSA-N moricizine hydrochloride Chemical compound [Cl-].C12=CC(NC(=O)OCC)=CC=C2SC2=CC=CC=C2N1C(=O)CC[NH+]1CCOCC1 GAQAKFHSULJNAK-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960002443 propafenone hydrochloride Drugs 0.000 description 1
- XWIHRGFIPXWGEF-UHFFFAOYSA-N propafenone hydrochloride Chemical compound Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 XWIHRGFIPXWGEF-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- SEBFKMXJBCUCAI-DBMPWETRSA-N silybin Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-DBMPWETRSA-N 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000429 sodium aluminium silicate Substances 0.000 description 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A slowly-releasing clinical medicine for durable blood concentration and decreasing the peaks and valleys of blood concentration is a solid disperser prepared from multiple chemically synthesized clinic medicines and the slowly-releasing aggregate. Its preparing process is also disclosed.
Description
[technical field] the present invention relates to multiple medicine and preparation method thereof, particularly slow releasing preparation of medicine and preparation method thereof.
[background technology]
The research and development of slow releasing preparation, the history surplus in the of existing so far 40 year, it is in environment provided, non-lentamente on request perseverance is captured release, the preparation that medication every day number of times and corresponding ordinary preparation reduce once more at least or prolong to some extent blanking time of medication.This preparation can make human body keep this kind blood drug level to reach the long time, do not descend quickly the ordinary preparation and do not resemble, thereby " peak valley " phenomenon that can avoid the ordinary preparation frequent drug administration to be occurred, safety, effectiveness or the adaptability of medicine are increased, thereby reduced the medication number of times, greatly facilitate the patient, particularly the patient of long-term prescription.Peroral dosage form commonly used has matrix tablet, micropore bag pellicle controlled release tablet, laser osmotic pumps, composite particles chamber capsule, label chamber capsule, Entogastric lingering preparation, controlled release suspensoid, drop pill etc.; External preparation has eye therapy system, oral cavity sticking tablet, indoor knot medicine device, transdermal clam medicine system etc.; Injection has water suspendible chaste tree, newborn thorn, liposome, microsphere etc.Tablet is with its taking convenience, and preparation technology is simple relatively, and quality is easy to advantage such as control becomes most widely used, the most sophisticated dosage form of technology of slow releasing preparation research and development.Capsule is also with its taking convenience, and preparation technology is simple relatively, and quality such as is easy to control at advantage becomes a wider dosage form of slow releasing preparation research and development application prospect.Film coating sustained-release and controlled release preparation packs the suitable clothing layer of one deck on the surface of label and piller, it is dissolved under certain condition or be partly dissolved and discharge medicine, can reach the sustained-release and controlled release effect.Its principle belongs to diffusion and discharges, and the energy is based on the osmotic pressure of film intracavity, or the stripping dispersal behavior coated slow release controlled release preparation of drug molecule in polymer is one of type of extensive use in the oral sustained release controlled release preparation.
Slow releasing preparation belongs to third generation preparation in the development process of pharmaceutics.In recent years, the research and development development of slow releasing preparation rapidly, the slow releasing preparation that with the Western medicine is material medicine has carried out a large amount of research at pharmacokinetics design principle, adjuvant and moulding process, biopharmaceutics characteristic aspects such as (comprising medicine inside and outside release rule and influence thereof), and existing many sophisticated kinds such as aminophylline slow releasing tablet, cefaclor slow releasing tablet, cefalexin slow releasing capsule etc. are widely used in clinically.Chinese medicine is more complicated in this regard, the Chinese medicine compound preparation active component is often indeterminate, thereby cause in its dissolubility, partition coefficient, the stability in Digestive system and the body and the logical suitable property of the combination rate of blood plasma, medicine pK value and biomembrane between relation etc. indeterminate, thereby increased the difficulty of preparation, but it is clinical that more existing at present sophisticated kinds are used for, as ZHENGQINGFENGTONGNING slow releasing tablet, aescine gel sustained-release preparation etc.
According to its preparation technology's difference, slow releasing preparation can be divided into piller, capsule, matrix tablet, coated pellets matrix tablet, film coating matrix tablet, Entogastric lingering floating type slow releasing tablet, the outstanding agent of slow release dry powder, oral sustained release membrane, sustained-release dropping pill etc.Used substrate comprises hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc.; Erodible sustained-release matrix material is as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc.; Water-insoluble sustained-release matrix material is as ethyl cellulose, zein etc.Along with being on the increase of substrate kind, preparation technology's is ripe day by day perfect, and slow releasing agent is extensive day by day in the application of Chinese-western medicine preparation, therefore existing medicine is carried out modified form, produce more medicament slow release dosage form, will greatly enrich drug market, improve quality of medical care.
[summary of the invention]
The purpose of this invention is to provide slow releasing preparation of multiple medicine and preparation method thereof.
The present invention studies the medicine that uses clinically at present multiple by experiment, has carried out modified form, changes slow releasing preparation into from existing tablet, capsule, oral liquid etc.Utilize medicament slow release framework material hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc.; Erodible sustained-release matrix material is as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc.; Water-insoluble sustained-release matrix material, be aided with other common drug adjuvant as substrate such as ethyl cellulose, zein and selected medicine material and make solid preparation, make the non-lentamente as requested constant release of medicine, safety, effectiveness or the adaptability of medicine are increased, thereby reduced the medication number of times, greatly facilitate the patient, particularly the patient's of long-term prescription use.
Wherein, selected medicine by following one or more medicines and its esters (as sodium salt, potassium salt, hydrochlorate, sulfate, hydrobromate, tartrate, fumarates etc.) one-tenth of derivant is grouped into: celecoxib (Celecoxib), Quetiapine (quetiapine), the complexing agent of amlodipine/benazepril (amlodipine/Benazepril), topiramate (topiramate), methylphenidate (Methylphenidate Hydrochloride), the complexing agent of metformin and glibenclamide (Metformin Hydrochloride and Glibenclamide Tablets), cefprozil (cefprozil), cefdinir (Cefdinir), tizanidine hydrochloride (Tizanidine Hydrochloride), nitrofurantoin (Nitrofurantion), ranitidine (ranitidine), rosiglitazone adds metformin (rosiglitazone/Metformin Hydrochloride), neurosedyn (Thalidomide), Memantine hydrochloride (Akatinol), galantamine (Galanthamine), cilostazol (Cilostazol), amoxicillin (Amoxicillin), amoxicillin/dicloxacillin (Amoxicillin/dicloxacillin), amoxicillin/flucloxacillin (Amoxicillin/Flucloxacillin), CEFUROXIME AXETIL (cefuroxime axetil), Cefteram Pivoxil (Cefteram Pivoxil), erythromycin (Erythromycin), midecamycin (Midecamycin), acetylspiramycin (Acetylspiramycin), norfloxacin (norfloxacin), berberine (Berberine Hydrochloride), amitriptyline (Amintriptyline), doxepin (Doxepin Hydrochloride), oxazepam (Oxazepam), cinmetacin (Cinmetacin), benzydamine (Benzydamine), mefenamic acid (Mefenamic Acid), meclofenamic acid (Meclofenamic Acid), tolmetin (tolmetin), fenoprofen calcium (Fenoprofen), phenprobamate (Phenprobamate), tripterygium glycosides (Tripterysium Glucosides), tranilast (Tranilast), albuterol (Salbutamol), clorprenaline (Clorprenaline), hexoprenaline (Hexoprenaline), terbutaline (Terbutaline), tulobuterol (Tulobuterol Hydrochloride), clenbuterol (Clenbuterol Hydrochloride), procaterol (Procaterol), moracizine (Moricizine Hydrochloride), phenytoin Sodium (Phenytoin Sodium), mexiletine (Mexiletine hydrochloride), tocainide (tocainide), aprindine (Aprindine), Propafenone (Propafenone Hydrochloride), oxprenolol (Oxprenolol), pindolol (pindolol), pentaerithrityl tetranitrate (Tetranitrate), perhexiline (perhexiline), nicorandil (Nicorandil), efloxate (Efloxatem), carbocromen (carbocromen), puerarin (Puerarin), troxerutin (Troxerutin), tolperisone (Tolperisone), pyritinol (Pyritinol), reserpine (Reserpine), hydralazine (Hydralazine), bendazol (DibazolHydrochloride), captopril (captopril), clofibrate (Clofibrate), propylene glycol alginate sodium sulfate (Alginric SodiumDiester), Glucuronic acid lactone (Glucurolactone), oleanolic acid (oleanolic acid), silymarin (silymarin), polygynax (Neomycin Sulfate), methylthiouracil (methylthiouracil), tolbutamide (tolbutamide).
Wherein said slow releasing preparation is made up of medicine and substrate as active component, its Chinese medicine: sustained-release matrix material=1: 0.10-1: 50.0.Described substrate comprises the medicament slow release framework material: hydrophilic gel medicament slow release framework material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc.; Erodible medicament slow release framework material is as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc.; Water-insoluble drug sustained-release matrix material comprises as ethyl cellulose, zein etc. and other additional materials:
1, diluent (filler): for example Icing Sugar, gelatin, glycerol, arabic gum, starch, dextrin, lactose, glucose, mannitol, calcium sulfate, calcium hydrogen phosphate, tricalcium phosphate, gelatinized corn starch, syrup, maltose, gelatine size, cellulose, Kaolin, sodium chloride, modified starch (Sta-RX1500), microcrystalline Cellulose etc., wherein Icing Sugar has sucrose, maltose, dextrinose, dextrinose oligosaccharide, panose, cottonseed sugar, stachyose, oligofructose, fructose, inulin, protein sugar, stevioside, xylitol, maltose alcohol, sorbitol;
2, binding agent: for example water, ethanol, starch, gelatin, sucrose, glucose, dextran, syrup, lactose, arabic gum, sodium alginate, gelatine size, polyvinylpyrrolidone, Polyethylene Glycol, methylcellulose, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, maltose, sucrose dextrin copolymer;
3, disintegrating agent: for example starch (corn and potato starch), cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, pectin, carboxymethyl cellulose, microcrystalline Cellulose, tween 80, sodium laurylsulfate, stearyl alcohol sodium sulfonate, kaolin.
4, lubricant: for example stearic acid, calcium stearate, magnesium stearate, zinc stearate, hydrogenated vegetable oil, polyoxyethylene monostearate, light mineral oil, liquid paraffin, boric acid, sodium chloride, sodium benzoate, sodium acetate, enuatrol, sodium laurylsulfate (magnesium), single Laurel sucrose acid ester, adipic acid, fumaric acid, three triacetins, Polyethylene Glycol
1500～20000
5, fluidizer: for example starch, purified talc, differential silica gel, pyrolytic silicon dioxide, hydrated sodium aluminosilicate.
Wherein said preparation type comprises slow releasing tablet, slow-release pill preparation, slow release capsule preparation etc.
By the preparation method of following slow releasing preparation provided by the present invention, can further understand the present invention, but following description not a limitation of the invention:
1, the preparation method of slow releasing tablet
With the medicine is primary raw material, according to certain ratio, adds medicament slow release framework material and additional materials as substrate, is prepared from through specific technology, apparatus processing again.Specific as follows:
(1) prescription: medicine+substrate;
Medicine: be foregoing medicine and its esters (as sodium salt, potassium salt, hydrochlorate, sulfate, hydrobromate, tartrate, fumarate etc.) derivant.
Substrate: include the medicament slow release framework material: hydrophilic gel medicament slow release framework material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc.; Erodible medicament slow release framework material is as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc.; Water-insoluble drug sustained-release matrix material is as one or more composition and additional materials of ethyl cellulose, zein etc., its Chinese medicine: sustained-release matrix material=1: 0.10-1: 50.0.
(2) preparation technology: concrete implementation step is as follows:
Method one: according to certain ratio with medicine, erodible sustained-release matrix material, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc. and the additives mix homogeneously of milling, direct compression or dry granulation behind the adding lubricant, tabletting or elder generation add typical binders granulation, drying behind the adding lubricant, add the lubricant tabletting again.
Method two: according to certain ratio with medicine, erodible sustained-release matrix material, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and additives mill jointly mix after, again with hydrophilic gel sustained-release matrix material, as mixing such as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomers, direct compression or dry granulation behind the adding lubricant, tabletting or elder generation add typical binders granulation, drying behind the adding lubricant, add the lubricant tabletting again.
Method three: according to certain ratio with medicine, additives and water-insoluble sustained-release matrix material, alcoholic solution mix homogeneously as ethyl cellulose, zein etc., add hydrophilic gel sustained-release matrix material, as mixing granulations such as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomers, dry, add lubricant, tabletting gets finished product.
Method four: according to certain ratio with water-soluble components in medicine, the described additives and water-insoluble sustained-release matrix material, alcoholic solution mix homogeneously or dissolving as ethyl cellulose, zein etc., vacuum drying, pulverize, add hydrophilic gel sustained-release matrix material, as mixing such as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomers, add the lubricant tabletting again behind adding lubricant direct compression or the dry granulation and get finished product.
Method five: with medicine, water-insoluble sustained-release matrix material, even with additives and mix lubricant as ethyl cellulose, zein etc., tabletting gets finished product according to certain ratio.
2, the preparation method of slow releasing capsule
With the medicine is primary raw material, according to certain ratio, adds medicament slow release framework material and additional materials as substrate, is prepared from through specific technology, apparatus processing again.Specific as follows:
(1) prescription: medicine+substrate;
Medicine: be foregoing medicine and its esters (as sodium salt, potassium salt, hydrochlorate, sulfate, hydrobromate, tartrate, fumarate etc.) derivant.
Substrate: include the medicament slow release framework material: hydrophilic gel medicament slow release framework material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc.; Erodible medicament slow release framework material is as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc.; Water-insoluble drug sustained-release matrix material is as one or more composition and additional materials of ethyl cellulose, zein etc., its Chinese medicine: sustained-release matrix material=1: 0.10-1: 50.0.
(2) preparation technology: concrete implementation step is as follows:
Method one: according to certain ratio with medicine, erodible sustained-release matrix material, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc. and the additives mix homogeneously of milling, dry method or wet method are made slow-release pill or granule, add or do not add additives, be packed in the hard capsule.
Method two: according to certain ratio with medicine and additives mill jointly mix after, make slow-release pill or granule with dry method or wet method, the erodible sustained-release matrix material of reuse, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and/or hydrophilic gel sustained-release matrix material, as solution such as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomers is that coating material is to ball pericardium clothing, add or do not add additives, be packed in the hard capsule.
Method three: according to certain ratio with medicine, erodible sustained-release matrix material, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc. and the additives mix homogeneously of milling, dry method or wet method are made slow-release pill or granule, the erodible sustained-release matrix material of reuse, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and/or hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, solution such as carbomer are that coating material is to ball pericardium clothing, add or do not add additives, be packed in the hard capsule
Method four: according to certain ratio with water-soluble components in medicine, the described additives and water-insoluble sustained-release matrix material, alcoholic solution mix homogeneously or dissolving as ethyl cellulose, zein etc., vacuum drying, pulverize, add hydrophilic gel sustained-release matrix material, as mixing such as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomers, dry method or wet method are made slow-release pill or granule, add or do not add additives, be packed in the hard capsule.
Method five: according to certain ratio with medicine, water-soluble components in the described additives and water-insoluble sustained-release matrix material, as ethyl cellulose, the alcoholic solution mix homogeneously or the dissolving of zein etc., vacuum drying, pulverize, add hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, mixing such as carbomer, dry method or wet method are made slow-release pill or granule, the erodible sustained-release matrix material of reuse, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and/or hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, solution such as carbomer are that coating material is to ball pericardium clothing, add or do not add additives, be packed in the hard capsule.
3, the preparation method of sustained-release dropping pill
With the medicine is primary raw material, according to certain ratio, adds medicament slow release framework material and additional materials as substrate, is prepared from through specific technology, apparatus processing again.Specific as follows:
(1) prescription: medicine+substrate;
Medicine: be foregoing medicine and its esters (as sodium salt, potassium salt, hydrochlorate, sulfate, hydrobromate, tartrate, fumarate etc.) derivant.
Substrate: include the medicament slow release framework material: hydrophilic gel medicament slow release framework material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc.; Erodible medicament slow release framework material is as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc.; Water-insoluble drug sustained-release matrix material is as one or more composition and drop pill additional materials of ethyl cellulose, zein etc., if any Polyethylene Glycol
(2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, stearic acid, sodium stearate, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyethers etc., its Chinese medicine: sustained-release matrix material=1: 0.10-1: 50.0.
(2) preparation technology: concrete implementation step is as follows:
Drop pill can improve the dissolution of insoluble drug, so be the better dosage form of preparation insoluble drug sustained-release preparation.
Method one: according to certain ratio with medicine, erodible sustained-release matrix material, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc. and the drop pill additives mix homogeneously of milling, adopt water-bath, oil bath or other mode of heating, mixed material is heated to fusion, stir, insert on the drop pill machine with suitable speed, splash in 40 →-40 ℃ the condensing agent.Condensing agent can be any one or a few in liquid paraffin, methyl-silicone oil, the vegetable oil, and type to be shrunk to takes out, and removes the surface condensation agent, dry.
Method two: according to certain ratio with medicine, erodible sustained-release matrix material, as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and hydrophilic gel sustained-release matrix material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc. and the drop pill additives mix homogeneously of milling, adopt water-bath, oil bath or other mode of heating, mixed material is heated to fusion, stir, insert on the drop pill machine with suitable speed, splash in 40 →-40 ℃ the condensing agent.Condensing agent can be any one or a few in liquid paraffin, methyl-silicone oil, the vegetable oil, type to be shrunk to, take out, remove the surface condensation agent, dry, reuse erodible sustained-release matrix material as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc. and/or hydrophilic gel sustained-release matrix material, is that coating material is to ball pericardium clothing as solution such as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomers.
The medicament slow release preparation that [beneficial effect] is involved in the present invention utilizes the sustained-release matrix material to comprise hydrophilic gel medicament slow release framework material, as hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer etc.; Erodible medicament slow release framework material is as stearic acid, hexadecanol, octadecanol, Polyethylene Glycol etc.; Water-insoluble drug sustained-release matrix material is made solid dispersion as ethyl cellulose, zein etc. for substrate and medicine material, makes medicine medicine after administration can be on request slowly continue to discharge keeping effective blood concentration, thereby reaches long-acting.
Compare with conventional formulation, medication preparation becomes to have its special advantages behind the slow releasing preparation: (1) reduces administration number of times, improves patient's compliance of taking medicine; (2) reduce the blood concentration peak valley phenomenon, improve drug effect and drug safety: (3) reduce the accumulated dose of medication, so that minimum dose reaches greatest treatment efficacy; (4) after medicine is made slowly released and controlled-drug delivery system with suitable carrier, the absorption of medicine and the main character decision that distributes by carrier, therefore select the appropriate carriers material according to clinical requirement, not only can conduct drugs to the particular target organ, can also improve the physicochemical property and the pharmacologically active of medicine to a certain extent, have broad clinical application prospect.
[specific implementation method]
By following concrete embodiment, can further understand the present invention, but following example not a limitation of the invention.
The preparation of embodiment 1-amoxicillin slow release sheet
Method: get amoxicillin 375 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 375mg/ sheet.Through drug release determination, meet the requirements.
The capsular preparation of embodiment 2-amoxicillin slow release
Method: get amoxicillin 187.5 grams, hydroxypropyl methylcellulose 50 grams, lactose 10 grams, ethyl cellulose 15 grams, carbomer 2 grams, calcium hydrogen phosphate 50 grams respectively, cross 80 mesh sieves respectively, put the mixer mixing, add concentration and be 60% ethanol water as wetting agent and stir and make soft material, cross 16 mesh sieves and granulate, 60 ℃ of dryings of granule 1 hour, 16 mesh sieve granulate add magnesium stearate 0.5 gram and Pulvis Talci 0.5 gram, mixing again, encapsulated, containing medication amount is the 187.5mg/ grain.Through drug release determination, meet the requirements.
The preparation of embodiment 3-Amoxicillin Sodium sustained-release dropping pill
Method: get respectively, stearic acid 11 gram, polyethylene glycol 6000 20 grams, carbomer 1 gram, mix homogeneously, add Amoxicillin Sodium raw material powder 18 grams again, fully mix, adopt electrically heated mode with the supplementary material mixture heated that makes to molten condition, adopt homemade special drilling pill machine, regulate its water dropper temperature and make it remain on 90 ℃ (error＜2%); With the methyl-silicone oil is condensing agent, the refrigeration control system of regulating the drop pill machine makes the temperature of condensing agent remain on 20 →-15 ℃ (error＜5%), according to the given method of the front preparation technology system of dripping, wait to take out behind the type of being shrunk to again, remove the surface condensation agent, dry, make the drop pill that contains medicine 18mg/ grain, carry out the mensuration of rounding rate (%), the ball method of double differences different (%), dissolution and hardness then, the rounding rate is 82% as a result, the ball method of double differences is different from 10%, and hardness is qualified.Through dissolution determination, meet the requirements.
The preparation of embodiment 4-celecoxib slow releasing tablet
Method: get celecoxib 200 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 200mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 5-quetiapine fumarate slow releasing tablet
Method: get quetiapine fumarate 25 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 25mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 6-amlodipine/benazepril slow releasing tablet
Method: get amlodipine 5 grams, benazepril 20 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 25mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 7-topiramate slow releasing tablet
Method: get topiramate 100 grams, hydroxypropyl cellulose 50 grams, lactose 50 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 8-methylphenidate hydrochloride slow releasing tablet
Method: get methylphenidate hydrochloride 10 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 10mg/ sheet.Through drug release determination, meet the requirements.
The preparation of the composite slow release sheet of embodiment 9-metformin and glibenclamide
Method: get metformin 250 grams, glibenclamide 2.5 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation, adding magnesium stearate mixes, tabletting gets finished product, and containing medication amount is the 252.5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 10-cefprozil slow releasing tablet
Method: get cefprozil 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 11-cefdinir slow releasing tablet
Method: get cefdinir 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 12-tizanidine hydrochloride slow releasing tablet
Method: get tizanidine hydrochloride 1 gram, hydroxypropyl cellulose 50 grams, lactose 150 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 1mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 13-nitrofurantoin slow releasing tablet
Method: get nitrofurantoin 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 14-ranitidine slow releasing tablet
Method: get amoxicillin 150 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 150mg/ sheet.Through drug release determination, meet the requirements.
Embodiment 15-rosiglitazone adds the preparation of metformin slow releasing tablet
Method: get rosiglitazone 250 grams respectively, metformin 2 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams, mix homogeneously, dry granulation, add magnesium stearate and mix, tabletting gets finished product, and containing medication amount is the 252mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 16-neurosedyn slow releasing tablet
Method: get neurosedyn 25 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 25mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 17-Memantine hydrochloride slow releasing tablet
Method: get Memantine hydrochloride 10 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 10mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 18-galantamine slow releasing tablet
Method: get amoxicillin 10 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 10mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 19-slow released cilostazol sheet
Method: get amoxicillin 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 20-amoxicillin/dicloxacillin slow releasing tablet
Method: get Amoxicillin Sodium 250 grams, dicloxacillin sodium 125 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation, adding magnesium stearate mixes, tabletting gets finished product, and containing medication amount is the 375mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 21-amoxicillin/flucloxacillin slow releasing tablet
Method: get amoxicillin 375 grams, flucloxacillin 125 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 375mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 22-CEFUROXIME AXETIL slow releasing tablet
Method: get CEFUROXIME AXETIL 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 23-Cefteram Pivoxil slow releasing tablet
Method: get Cefteram Pivoxil 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 24-erythromycin slow releasing tablet
Method: get erythromycin 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 25-midecamycin slow releasing tablet
Method: get midecamycin 200 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 200mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 26-acetylspiramycin slow releasing tablet
Method: get acetylspiramycin 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 27-norfloxacin slow releasing tablet
Method: get norfloxacin 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 28-berberine slow releasing tablet
Method: get berberine 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 29-amitriptyline slow releasing tablet
Method: get amitriptyline 50 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 50mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 30-doxepin slow releasing tablet
Method: get doxepin 25 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 25mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 31-oxazepam slow releasing tablet
Method: get oxazepam 30 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 30mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 32-cinmetacin slow releasing tablet
Method: get cinmetacin 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 33-benzydamine slow releasing tablet
Method: get benzydamine 50 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 50mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 34-mefenamic acid slow releasing tablet
Method: get mefenamic acid 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 35-meclofenamic acid slow releasing tablet
Method: get meclofenamic acid 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 36-tolmetin slow releasing tablet
Method: get tolmetin 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 37-fenoprofen sustained release tablet of calcium
Method: get fenoprofen calcium 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 38-phenprobamate slow releasing tablet
Method: get phenprobamate 200 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 200mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 39-tripterygium glycosides slow releasing tablet
Method: get tripterygium glycosides 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 40-tranilast slow releasing tablet
Method: get tranilast 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 41-albuterol slow releasing tablet
Method: get albuterol 1 gram, hydroxypropyl cellulose 50 grams, lactose 150 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 1mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 42-clorprenaline slow releasing tablet
Method: get clorprenaline 5 grams, hydroxypropyl cellulose 50 grams, lactose 150 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 43-hexoprenaline slow releasing tablet
Method: get hexoprenaline 1 gram, hydroxypropyl cellulose 50 grams, lactose 150 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 1mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 44-terbutaline slow releasing tablet
Method: get terbutaline 2.5 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 2.5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 45-tulobuterol slow releasing tablet
Method: get tulobuterol 0.5 gram, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 0.5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 46-clenbuterol slow releasing tablet
Method: get clenbuterol 2.5 grams, hydroxypropyl cellulose 50 grams, lactose 150 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 2.5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 47-procaterol slow releasing tablet
Method: get 25 milligrams of procaterols, hydroxypropyl cellulose 50 grams, lactose 150 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 25ug/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 48-moracizine slow releasing tablet
Method: get moracizine 50 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 50mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 49-phenytoin Sodium slow releasing tablet
Method: get phenytoin Sodium 50 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 50mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 50-mexiletine (Mexiletine hydrochloride) 300mg slow releasing tablet
Method: get mexiletine 300 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 300mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 51-tocainide slow releasing tablet
Method: get tocainide 200 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 200mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 52-aprindine slow releasing tablet
Method: get aprindine 50 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 50mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 53-Propafenone slow releasing tablet
Method: get Propafenone 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 54-oxprenolol slow releasing tablet
Method: get oxprenolol 80 grams, hydroxypropyl cellulose 50 grams, lactose 50 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 80mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 55-pindolol slow releasing tablet
Method: get pindolol 5 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 56-pentaerithrityl tetranitrate slow releasing tablet
Method: get pentaerithrityl tetranitrate 10 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 10mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 57-perhexiline slow releasing tablet
Method: get perhexiline 40 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 40mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 58-nicorandil slow releasing tablet
Method: get nicorandil 5 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 59-efloxate slow releasing tablet
Method: get efloxate 20 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 20mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 60-carbocromen slow releasing tablet
Method: difference card taking POLO gram in the Meng 75, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 restrain, Macrogol 4000 30 grams, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 75mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 61-puerarin sustained-release sheet
Method: get puerarin 375 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 375mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 62-troxerutin slow releasing tablet
Method: get troxerutin 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 63-tolperisone slow releasing tablet
Method: get tolperisone 50 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 50mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 64-pyritinol slow releasing tablet
Method: get pyritinol 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 65-reserpine slow releasing tablet
Method: get reserpine 0.5 gram, hydroxypropyl cellulose 50 grams, lactose 150 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 0.5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 66-hydralazine slow releasing tablet
Method: get hydralazine 10 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 10mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 67-bendazol slow releasing tablet
Method: get bendazol 10 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 10mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 68-captopril slow releasing tablet
Method: difference card taking Top profit 12.5 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 restrain, carbomer 1 restrains, Macrogol 4000 30 grams, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 12.5mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 69-clofibrate slow releasing tablet
Method: get amoxicillin 25 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 25mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 70-propylene glycol alginate sodium sulfate slow releasing tablet
Method: get propylene glycol alginate sodium sulfate 50 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 50mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 71-Glucuronic acid lactone slow releasing tablet
Method: get Glucuronic acid lactone 200 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 200mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 72-oleanolic acid slow releasing tablet
Method: even up pier fruit acid 10 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 10mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 73-silymarin slow releasing tablet
Method: water intaking flies silibin 35 grams, hydroxypropyl cellulose 50 grams, lactose 100 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 35mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 74-polygynax slow releasing tablet
Method: get polygynax 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 75-methylthiouracil slow releasing tablet
Method: get methylthiouracil 100 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 100mg/ sheet.Through drug release determination, meet the requirements.
The preparation of embodiment 76-tolbutamide slow releasing tablet
Method: get tolbutamide 250 grams, hydroxypropyl cellulose 50 grams, lactose 10 grams, microcrystalline Cellulose 10 grams, carbomer 1 gram, Macrogol 4000 30 grams respectively, mix homogeneously, dry granulation adds magnesium stearate and mixes, tabletting gets finished product, and containing medication amount is the 250mg/ sheet.Through drug release determination, meet the requirements.
Claims (9)
1, the slow releasing preparation of multiple medicine is characterized in that: it contains substantially as the medicine of effective ingredient and slow release framework material, its Chinese medicine: sustained-release matrix material=1: 0.10-1: 50.0.
2, slow releasing preparation according to claim 1 is characterized in that: described sustained-release matrix material is one or more a combination in any of hydrophilic gel sustained-release matrix material, erodible sustained-release matrix material, water-insoluble sustained-release matrix material.
3. slow releasing preparation according to claim 1 is characterized in that: described medicine as active component is that the one-tenth by following one or more medicines and salt derivative thereof is grouped into: celecoxib, Quetiapine, amlodipine/benazepril, topiramate, methylphenidate, the complexing agent of metformin and glibenclamide, cefprozil, cefdinir, the tizanidine, nitrofurantoin, ranitidine, rosiglitazone adds metformin, neurosedyn, Memantine hydrochloride, galantamine, cilostazol, the amoxicillin, amoxicillin/dicloxacillin, amoxicillin/flucloxacillin, CEFUROXIME AXETIL, Cefteram Pivoxil, erythromycin, midecamycin, acetylspiramycin, norfloxacin, berberine, amitriptyline, doxepin, oxazepam, cinmetacin, benzydamine, mefenamic acid, meclofenamic acid, tolmetin, fenoprofen calcium, phenprobamate, tripterygium glycosides, tranilast, albuterol, clorprenaline, hexoprenaline, terbutaline, tulobuterol, clenbuterol, procaterol, moracizine, phenytoin Sodium, mexiletine, tocainide, aprindine, Propafenone, oxprenolol, pindolol, pentaerithrityl tetranitrate, perhexiline, nicorandil, efloxate, carbocromen, puerarin, troxerutin, tolperisone, pyritinol, reserpine, hydralazine, bendazol, captopril, clofibrate, propylene glycol alginate sodium sulfate, Glucuronic acid lactone, oleanolic acid, silymarin, polygynax, methylthiouracil, tolbutamide.
4, sustained-release matrix material according to claim 2 is characterized in that: described hydrophilic gel sustained-release matrix material is one or more a combination in any of hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer; Described erodible sustained-release matrix material is one or more the combination in any in stearic acid, hexadecanol, octadecanol, the Polyethylene Glycol; Described water-insoluble sustained-release matrix material is that ethyl cellulose is or/and zein.
5, slow releasing tablet according to claim 1 is characterized in that: be added with lubricant and filler, binding agent, disintegrating agent, lubricant, fluidizer in the described matrine slow-release tablet.
6, slow releasing preparation according to claim 1 is characterized in that: preparation type comprises slow releasing tablet, slow-release pill preparation, slow release capsule preparation.
7, the preparation method of slow releasing tablet according to claim 5, it is characterized in that: with medicine, sustained-release matrix material, the additives mix homogeneously of milling, direct compression or dry granulation behind the adding lubricant, tabletting or elder generation add typical binders granulation, drying behind the adding lubricant, add the lubricant tabletting again.
8, the preparation method of slow-release pill preparation according to claim 5, it is characterized in that: described sustained-release dropping pill is made up of active constituents of medicine that includes antibiotics and substrate, adopt water-bath, oil bath or other mode of heating, mixed material is heated to fusion, stir, insert on the drop pill machine, splash in 40 →-40 ℃ the condensing agent liquid paraffin, methyl-silicone oil, vegetable oil any one or a few with suitable speed, drying forms, and its mesostroma is by including Polyethylene Glycol
(2000,4000,6000,8000,10000,20000), one or more one-tenth in polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, stearic acid, sodium stearate, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyethers and the described sustained-release matrix material are grouped into.
9, the preparation method of slow release capsule preparation according to claim 5, it is characterized in that: with medicine, sustained-release matrix material, the additives mix homogeneously of milling, direct compression or dry granulation behind the adding lubricant, tabletting or elder generation add typical binders granulation, drying behind the adding lubricant, add the lubricant tabletting again.
Priority Applications (44)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510104989 CN1957928A (en) | 2005-09-26 | 2005-09-26 | Controlled release preparation of clinical treating medication, and fabricating method |
| CNA2006100986302A CN101011363A (en) | 2005-09-26 | 2006-07-10 | Slow release tablet of amoxicillin |
| CNA2006101530231A CN101002740A (en) | 2005-09-26 | 2006-09-20 | Slow release preparation of compactin |
| CNA2006101529111A CN101015531A (en) | 2005-09-26 | 2006-09-20 | Sustained release preparation of dibazole |
| CNA200610152915XA CN101015535A (en) | 2005-09-26 | 2006-09-20 | Sustained release preparation of perhexiline |
| CNA2006101530161A CN101002736A (en) | 2005-09-26 | 2006-09-20 | Slow-release preparation containing polyheteroside of tripterygium wilfordii |
| CNA2006101529145A CN101015534A (en) | 2005-09-26 | 2006-09-20 | Sustained release preparation of phenprobamate |
| CNA2006101530212A CN101002739A (en) | 2005-09-26 | 2006-09-20 | Slow release preparation of ranitidine |
| CNA2006101529107A CN101015530A (en) | 2005-09-26 | 2006-09-20 | Sustained release preparation of doxepin |
| CNA2006101530227A CN101006988A (en) | 2005-09-26 | 2006-09-20 | Slow release preparation of puerarin |
| CNA2006101529126A CN101015532A (en) | 2005-09-26 | 2006-09-20 | Sustained release preparation of phenytoin sodiumslow release |
| CNA2006101530250A CN1994282A (en) | 2005-09-26 | 2006-09-20 | Sustained-release preparation of mexiletine |
| CNA2006101529130A CN101015533A (en) | 2005-09-26 | 2006-09-20 | Sustained release preparation of norfloxacin |
| CNA2006101530265A CN1994283A (en) | 2005-09-26 | 2006-09-20 | Sustained-release preparation of nicorandil |
| CNA2006101530208A CN101006987A (en) | 2005-09-26 | 2006-09-20 | Slow release preparation of erythromycin |
| CNA2006101530195A CN101036632A (en) | 2005-09-26 | 2006-09-20 | Sustained release preparation of cinmetacin |
| CNA2006101530180A CN101002738A (en) | 2005-09-26 | 2006-09-20 | Slow release preparation containing tolbutamide |
| CNA2006101530246A CN1994281A (en) | 2005-09-26 | 2006-09-20 | Sustained-release preparation of midecamycin |
| CNA2006101530176A CN101002737A (en) | 2005-09-26 | 2006-09-20 | Slow release preparation of Kui-Liu-Ping |
| CNA2006101530797A CN101006990A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of cilostazol |
| CNA2006101530706A CN101002748A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of cephradine |
| CNA2006101530689A CN101002746A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of cefuroxime axetil |
| CNA2006101530674A CN101002745A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of cefdinir |
| CNA2006101529573A CN101011367A (en) | 2005-09-26 | 2006-09-21 | Slow release tablet of glucurolactone |
| CNA2006101530814A CN101006991A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of berberine |
| CNA200610153066XA CN101002744A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of cefalexin |
| CNA2006101530636A CN101002741A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of Sai-Mi-Xi-Bu |
| CNA2006101530693A CN101002747A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of cefaclor |
| CNA2006101530655A CN101002743A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of tizanidine |
| CNA2006101530640A CN101002742A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of silymarin |
| CNA2006101529588A CN101011368A (en) | 2005-09-26 | 2006-09-21 | Slow release tablet of troxerutin |
| CNA2006101530710A CN101002749A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of nitrofurantion |
| CNA2006101530725A CN101002750A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of pyrithione alcohol |
| CNA200610153080XA CN101002754A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of penthrit |
| CNA200610153073XA CN101002751A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of amitriptyline |
| CNA2006101529569A CN101011366A (en) | 2005-09-26 | 2006-09-21 | Slow release tablet of methylphenidate |
| CNA2006101530759A CN101006989A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of alginic sodium diester |
| CNA2006101530778A CN101002753A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of ethoxy flavonoid |
| CNA2006101529554A CN101011365A (en) | 2005-09-26 | 2006-09-21 | Slow release tablet of ampicillin |
| CNA2006101530763A CN101002752A (en) | 2005-09-26 | 2006-09-21 | Slow release preparation of tropyone |
| CNA2006101526151A CN101057835A (en) | 2005-09-26 | 2006-09-25 | Metformin glibenclamide slow-releasing preparation |
| CNA2006101526166A CN101011364A (en) | 2005-09-26 | 2006-09-25 | Slow release preparation of metformin rosiglitazone |
| CNA2006101526132A CN101015528A (en) | 2005-09-26 | 2006-09-25 | Sustained release preparation of amoxillin and flucloxacillin |
| CNA2006101526147A CN101015529A (en) | 2005-09-26 | 2006-09-25 | Sustained release preparation of amoxillin and dicloxacillin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510104989 CN1957928A (en) | 2005-09-26 | 2005-09-26 | Controlled release preparation of clinical treating medication, and fabricating method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1957928A true CN1957928A (en) | 2007-05-09 |
Family
ID=38069882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510104989 Pending CN1957928A (en) | 2005-09-26 | 2005-09-26 | Controlled release preparation of clinical treating medication, and fabricating method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1957928A (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101219140B (en) * | 2007-12-24 | 2011-06-01 | 重庆市莱美药物技术有限公司 | Benzydamine hydrochloride soluble tablet and preparation method thereof |
| CN102423313A (en) * | 2011-12-26 | 2012-04-25 | 盛世泰科生物医药技术(苏州)有限公司 | Compound sustained-release preparation of rosiglitazone and metformin hydrochloride |
| CN102000018B (en) * | 2010-02-09 | 2012-07-04 | 浙江大学宁波理工学院 | Solid dispersion containing celecoxib as well as preparation method and application thereof |
| CN102764239A (en) * | 2012-08-08 | 2012-11-07 | 成都医学院 | Propylthiouracil sustained release pellet |
| CN101700010B (en) * | 2009-10-30 | 2013-03-20 | 华南理工大学 | Slow-release bactericide for inhibiting growth of thiobacillus ferroxidana and preparation method thereof |
| CN103099796A (en) * | 2013-02-19 | 2013-05-15 | 青岛正大海尔制药有限公司 | Propylene glycol marinate sulfate-containing sustained-release preparation and preparation method thereof |
| CN103127027A (en) * | 2013-02-18 | 2013-06-05 | 青岛正大海尔制药有限公司 | Polysaccharide sulphate dropping pill |
| CN104623681A (en) * | 2014-11-26 | 2015-05-20 | 嘉应学院医学院 | Oleanolic acid based drug slow-release agent and preparation method thereof |
| CN104958271A (en) * | 2015-07-27 | 2015-10-07 | 青岛海之星生物科技有限公司 | Acetylspiramycin slow-release tablet and preparation method |
| CN104983720A (en) * | 2015-07-27 | 2015-10-21 | 青岛海之星生物科技有限公司 | Acetylspiramycin slow-release capsules and preparation method thereof |
| CN105412047A (en) * | 2015-12-03 | 2016-03-23 | 烟台东诚药业集团股份有限公司 | Skeleton type memantine hydrochloride slow-release capsule and preparation method thereof |
| CN106344531A (en) * | 2016-10-31 | 2017-01-25 | 浙江为康制药有限公司 | Nifedipine controlled-release tablet composition and preparation method thereof |
| CN106466396A (en) * | 2015-08-19 | 2017-03-01 | 贵州益佰女子大药厂有限责任公司 | A kind of Fuke Tiaojing sustained-release dropping pill and preparation method thereof |
| CN108295035A (en) * | 2018-02-28 | 2018-07-20 | 重庆希尔安药业有限公司 | Procaterol Hydrochloride piece and preparation method thereof |
| CN108969498A (en) * | 2017-05-31 | 2018-12-11 | 四川科瑞德制药股份有限公司 | A kind of Tizanidine sustained release preparation and its preparation process and purposes |
| CN109549967A (en) * | 2018-12-20 | 2019-04-02 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of sophora alapecuroides slow-releasing granules and preparation method thereof |
| CN111803498A (en) * | 2020-07-30 | 2020-10-23 | 重庆医科大学 | Preparation method and application of rosiglitazone and berberine adduct |
| CN113116860A (en) * | 2021-04-22 | 2021-07-16 | 海南通用三洋药业有限公司 | Amoxicillin capsule and preparation method thereof |
-
2005
- 2005-09-26 CN CN 200510104989 patent/CN1957928A/en active Pending
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101219140B (en) * | 2007-12-24 | 2011-06-01 | 重庆市莱美药物技术有限公司 | Benzydamine hydrochloride soluble tablet and preparation method thereof |
| CN101700010B (en) * | 2009-10-30 | 2013-03-20 | 华南理工大学 | Slow-release bactericide for inhibiting growth of thiobacillus ferroxidana and preparation method thereof |
| CN102000018B (en) * | 2010-02-09 | 2012-07-04 | 浙江大学宁波理工学院 | Solid dispersion containing celecoxib as well as preparation method and application thereof |
| CN102423313A (en) * | 2011-12-26 | 2012-04-25 | 盛世泰科生物医药技术(苏州)有限公司 | Compound sustained-release preparation of rosiglitazone and metformin hydrochloride |
| CN102764239A (en) * | 2012-08-08 | 2012-11-07 | 成都医学院 | Propylthiouracil sustained release pellet |
| CN103127027A (en) * | 2013-02-18 | 2013-06-05 | 青岛正大海尔制药有限公司 | Polysaccharide sulphate dropping pill |
| CN103099796A (en) * | 2013-02-19 | 2013-05-15 | 青岛正大海尔制药有限公司 | Propylene glycol marinate sulfate-containing sustained-release preparation and preparation method thereof |
| CN104623681A (en) * | 2014-11-26 | 2015-05-20 | 嘉应学院医学院 | Oleanolic acid based drug slow-release agent and preparation method thereof |
| CN104958271A (en) * | 2015-07-27 | 2015-10-07 | 青岛海之星生物科技有限公司 | Acetylspiramycin slow-release tablet and preparation method |
| CN104983720A (en) * | 2015-07-27 | 2015-10-21 | 青岛海之星生物科技有限公司 | Acetylspiramycin slow-release capsules and preparation method thereof |
| CN106466396A (en) * | 2015-08-19 | 2017-03-01 | 贵州益佰女子大药厂有限责任公司 | A kind of Fuke Tiaojing sustained-release dropping pill and preparation method thereof |
| CN106466396B (en) * | 2015-08-19 | 2020-01-10 | 贵州益佰女子大药厂有限责任公司 | Gynaecologic menstruation regulating sustained-release dropping pill and preparation method thereof |
| CN105412047A (en) * | 2015-12-03 | 2016-03-23 | 烟台东诚药业集团股份有限公司 | Skeleton type memantine hydrochloride slow-release capsule and preparation method thereof |
| CN106344531B (en) * | 2016-10-31 | 2019-07-30 | 浙江为康制药有限公司 | A kind of Nifedipine controlled-release tablet composition and preparation method thereof |
| CN106344531A (en) * | 2016-10-31 | 2017-01-25 | 浙江为康制药有限公司 | Nifedipine controlled-release tablet composition and preparation method thereof |
| CN108969498A (en) * | 2017-05-31 | 2018-12-11 | 四川科瑞德制药股份有限公司 | A kind of Tizanidine sustained release preparation and its preparation process and purposes |
| CN108969498B (en) * | 2017-05-31 | 2021-11-30 | 四川科瑞德制药股份有限公司 | Tizanidine hydrochloride sustained release preparation, preparation process and application thereof |
| CN108295035A (en) * | 2018-02-28 | 2018-07-20 | 重庆希尔安药业有限公司 | Procaterol Hydrochloride piece and preparation method thereof |
| CN109549967A (en) * | 2018-12-20 | 2019-04-02 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of sophora alapecuroides slow-releasing granules and preparation method thereof |
| CN111803498A (en) * | 2020-07-30 | 2020-10-23 | 重庆医科大学 | Preparation method and application of rosiglitazone and berberine adduct |
| CN113116860A (en) * | 2021-04-22 | 2021-07-16 | 海南通用三洋药业有限公司 | Amoxicillin capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1957928A (en) | Controlled release preparation of clinical treating medication, and fabricating method | |
| CN1111404C (en) | The oxybutynin formulations of controlled release | |
| CN1089471A (en) | Stable prolongation release oral dosage composition | |
| CN1271276A (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
| CN1527700A (en) | Compression method for preparing phenytoin dosage form | |
| CN1631247A (en) | Health food with hypoxia preventing and anti-fatigue function and preparation technique thereof | |
| CN1139382A (en) | Modified release 2-methyl-5-nitro-1-imidazolyl-ethanol compositions and methods of making and using same | |
| CN1460517A (en) | Compound danshen oral disintegrant tablet and its preparation method | |
| CN1931143A (en) | Orally taken control released trimetazidine medicine composition | |
| CN1270712C (en) | Felodipine controlled-release preparation | |
| CN1265785C (en) | Chrono-slow-releasing prepn. hydrochloride verapamil | |
| CN1623593A (en) | Solid instant preparation extracted from ginkgo leaf and its preparing process | |
| CN1217655C (en) | Fibrauretine slow releasing prepn | |
| CN100336511C (en) | Release-controlled oral Roxithromycin formulation | |
| CN1303990C (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN1965817A (en) | Sustained release tablet of glibenclamide and preparation process thereof | |
| CN1478467A (en) | Rapid disintegrate tablet in oral and its preparation method | |
| CN1723964A (en) | A medicine for treating cough and asthma and chronic bronchitis | |
| CN1293895C (en) | Oral disintegration tablet for laryngopathy and its preparing method | |
| CN101028518A (en) | Medicinal composition containing silver ester medicine and ibobulodine | |
| CN1895250A (en) | Gliquilone slow-releasing preparation | |
| CN1899287A (en) | Slow release medicinal composition for treating anxiety and its preparing method | |
| CN101011364A (en) | Slow release preparation of metformin rosiglitazone | |
| CN1552327A (en) | Oral ofloxacin control-sustained releasing medicinal composition | |
| CN1449750A (en) | Gabapentin slow -released composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |